How to expedite the adoption of alternative rapid microbiology methods

One of the main targets for the Technology Roadmapping Phorum is to reduce the testing times for bacteria (including mycoplasma), fungi and viruses in biological therapeutics from four weeks to just one or two days. It has made significant progress on understanding the challenges to achieving this goal, which are captured in the publication of its white paper Rapid detection of bacteria and viruses in bioprocess samples: justification, regulation, requirements and technologies—how can industry achieve broad adoption

 

The paper addresses the main factors preventing the use of alternative rapid microbiology methods (RMM) for testing to assure sterility and the absence of adventitious agents in the manufacturing process. Ultimately, it aims to move the industry towards the real-time release of drug products.

The project evolved out of the first edition of BioPhorum’s BioManufacturing Technology Roadmap. “One of the biggest desires from biomanufacturers was to shorten the testing time for release,” explained Audrey Chang, Head of Process Solution Services R&D at Merck. “Our group came together to ask, ‘What can we do to move towards that vision?’

“We recognized that implementing these newer technologies in a regulated environment is challenging, [in particular] demonstrating how they are at least equal to, if not better than, current methods. And so, we thought that if we could share this burden of validation as an industry, we could all benefit.”

 Challenges

Realizing that the scope of the initiative was huge, the workstream (comprising nine biomanufacturers, three supply partners and an innovation hub), quickly established a need to split the project into phases.

Phase 1 was the white paper, aimed at identifying the barriers, listening to end-users and finding ways to resolve those barriers. To achieve these goals, the team conducted a survey, which found that the overwhelming barrier cited was one of regulatory acceptance.

“We’ve got a whole new dawn of medical treatments,” said Morven McAlister, Senior Director, Regulatory & Validation Consultancy at Pall Biotech, “and these new technologies will need these rapid methods. There’s no way we can fully realize their potential if we don’t implement them. We’d like to be able to tie these to existing products as well.”

The survey also revealed the need for what McAlister calls “a playbook”—a guidance document that gives end-users “a tool that will help them understand what they need to do to qualify and validate these alternative rapid micro methods.”

Also, the costs and time associated with manufacturing and filing post-approval changes were raised as concerns. However, one key factor should also not be overlooked, added McAlister. “This wonderful collaboration is all going towards safety in trying to get drugs to the patient faster. It’s not just a case of reducing manufacturing costs, it is ultimately about patient safety.”

Three milestones

A key moment for the workstream came in October 2018 when, as part of a wider BioPhorum microbial control group, it met with the FDA.

Chang explained that today, companies approach the regulators individually with their method validation studies. In this manner, regulators view similar studies in a siloed approach. A more preferable approach would be a shared method validation, where comments and best practices would benefit both industry and regulators.

The discussions were extremely fruitful. “The take-home message for us was that [the FDA] were not only open to our group and what we were trying to do, they encouraged it,” said Chang.

According to Chang, this shows the power of BioPhorum and the feedback from the FDA was that “they really liked the fact that we went not as individual companies but as part of BioPhorum and we represented a consensus viewpoint.”

The project’s second key achievement was the survey, which showed that the interest and drive to implement RMM was widespread. “It really validated our premise that the low level of adoption was not related to a particular method or particular instrument” said Chang. “People recognized that they wanted to implement this and the roadblock was really more of a need for a procedure as to how do we move forward.”

According to Scott Hooper, Associate Director Microbiology at Merck Inc Kenilworth, NJ, the third triumph will be realized once the white paper is published as it will “give people a framework to deal with the barriers, not all of which are technical. There are a lot of different things that we have touched upon in the paper and I think it will provide the tools to move those forward.”

Next steps

“The next stage is to really understand what we have to do to come up with the playbook,” said McAlister. “This will also have regulatory input, which is important. Many others have come up with papers on how to qualify and validate such methods, but this one—because of the collaboration involved between end-users, suppliers, labs and regulators—will be a really powerful document for the industry.”

Phase 2 will see the team develop user requirement specifications to help guide vendors for technology development in this area.

“This paper defines the problem, but there’s a lot of things we want to do in terms of developing solutions and then, of course, implementation,” added Chang, who sees the initiative being a multi-year project—but one that will beat the 10-year timescale set out in the BioPhorum Roadmap.

For more information, contact the Phorum Facilitator Bela Green on bela@biophorum.com

Contact address

BioPhorum
The Gridiron Building
One Pancras Square
London
N1C 4AG

Newsletter subscribe

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.



© 2019 Biophorum Operations Group · All Rights Reserved

Registered Address: 5 Westbrook Court · 2 Sharrow Vale Road · Sheffield · S11 8YZ

Company Number 06794795 · VAT Number GB298617544

Driving progress in Cell & Gene Therapy

Now with 19 member companies and 183 subject matter experts, the BioPhorum Cell & Gene Therapy (C>) Phorum has made great strides since its formation[...]

Read More
Cell and Gene Therapy Phorum accelerates progress

The BioPhorum Cell & Gene Therapy Phorum has made significant progress since its creation in 2018 – from building networks and sharing knowledge to endorsing[...]

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
Industry bioassay approach helps to shape the future

In 2018, members of the Development Group Bioassay workstream came together to write a best practices paper on bioassay development. We are delighted to announce[...]

Read More
Sharing ideas on forced degradation

“Forced degradation studies are an important part of the drug lifecycle process as they can inform many aspects of drug development,” said Jennifer Halley, Principal[...]

Read More
The BioPhorum and USP collaborative journey to new standards

BioPhorum and United States Pharmacopeia (USP) share a common direction – to accelerate biopharma innovation, quality and progress through collaboration.

Read More
Proactive prioritization: a new tool for assessing raw material risk

The Raw Material Risk Management workstream has launched a new, raw material risk assessment tool aimed at helping industry identify and prioritize around the challenging[...]

Read More
How well can you handle SUS changes?  Take our surveys and see

BioPhorum delivery of value from the disposables five-year plan - supplier change notifications for single-use systems

Read More
Decision tree to support alignment of risk assessment for changes to single-use biomanufacturing systems

The BioPhorum single use change notification team has been working on developing and standardizing best practice for single use change notification since 2015.  The challenges[...]

Read More
PUPSIT – An update on BioPhorum/PDA work to develop a risk-based position
Read More
Driving the evolution of secondary packaging

How do we transition from large-batch manufacture to small-batch, high-value packaging runs?

Read More
Hi-tech ambitions for Fill Finish

The Fill Finish Phorum has recently embarked on a series of exciting and ambitious initiatives, exploring new technologies and processes to enhance the efficiency and[...]

Read More
Logistics collaboration hub: An opportunity for significant time and cost savings

Most biopharmaceutical manufacturers use a network of logistics service providers (LSPs) to deliver warehousing, transport and distribution services, and they are usually linked using customized,[...]

Read More
The ‘how to’ guide to implementing Agile in GxP

The publication of the Guidance on the use of Agile in a GxP Environment document in 2017 was well received.It described how the use of[...]

Read More
How smart is your maintenance?

Faster. Cheaper. Smarter. All companies are under pressure to achieve more with less, not least with their maintenance programs. But while ‘faster’ and ‘cheaper’ maintenance[...]

Read More
BioPhorum’s Maturity Assessment Tool gains momentum
Read More
Supply chain, forecasting and demand planning solutions gain momentum

The relationship between suppliers and manufacturers is one of the most crucial in biopharmaceutical manufacturing. This is especially the case when forecasting and supply planning.[...]

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
Removing the roadblocks to continuous biomanufacturing

Continuous downstream processing is increasingly seen as a feasible approach for manufacturing biologics. The industry recognises that it offers advantages over batch-based processing by:

Read More
Changing mindsets with a modular approach

Historically, manufacturers have used a ‘waterfall’ approach when designing and building their production facilities, sequentially resolving and specifying all aspects up front and in detail[...]

Read More
How do you bring technology roadmapping to life?

You use it to make change happen and that is exactly what the Phorum’s leaders did after the first edition of the Biomanufacturing Technology Roadmaps[...]

Read More
Slicing years off change implementation

As the first regulatory authority in Latin America to gain full membership of the International Council for Harmonization (ICH), the Brazilian Health Regulatory Agency (Anvisa)[...]

Read More
BioPhorum Regulatory Interaction: helping to open doors

To implement any change in the biopharmaceutical manufacturing industry it is important to engage with and collaborate with the regulators. Set up two years ago,[...]

Read More
Regulatory compliance: what lessons can be learned?

BioPhorum delivery of value from the disposables five-year plan - supplier change notifications for single-use systems

Read More
Navigating the maze of medical technology regulation: a solo voyage or a team effort?

Medical technology is a global business, generating annual revenues of over $400bn. The sector encompasses a broad range of technologies: from in-vitro diagnostics and diagnostic[...]

Read More

IaaS Cloud webinar recording play back
Read More
New BPIT guidance to align cloud services to regulatory requirements
Read More
Data Integrity and Agile Webinars to support industry response to regulators
Read More
How to validate informatics in CPV programs

The BioPhorum Continued Process Verification (CPV) and Informatics team has published a paper to support a risk-based approach for the validation of informatics systems for[...]

Read More
Continued Process Verification delivering real saving in time and money

More than 50 per cent of biopharma products on the market now have Continued Process Verification (CPV) plans in place.  Thanks to the CPV white[...]

Read More
A roadmap for the implementation of continued process verification

This article provides a roadmap draws on the content of the CPV case study to provide a step-by-step guide in a more accessible form.

Read More
How smart is your maintenance?

Faster. Cheaper. Smarter. All companies are under pressure to achieve more with less, not least with their maintenance programs. But while ‘faster’ and ‘cheaper’ maintenance[...]

Read More
Digital plant maturity model webinar replay
Read More
Digital Plant Maturity Model workstream to host webinar
Read More
New guidance available on Forecasting and Demand Planning to streamline supply chain performance
Read More
Host cell proteins poster

This poster presented at the BEBPA Conference, San Francisco builds and consolidates the information currently available in the industry for assessing process risk from Host[...]

Read More
Host cell protein risk assessment, an industry approach

Host cell protein (HCP) constitutes a significant class of process-related impurities in biological drugs.

Read More
BEBPA risk assessment workshop
Read More
PUPSIT – An update on BioPhorum/PDA work to develop a risk-based position
Read More
BioPhorum’s Maturity Assessment Tool gains momentum
Read More
Driving the evolution of secondary packaging

How do we transition from large-batch manufacture to small-batch, high-value packaging runs?

Read More